PuraPharm Raises HK$20 Million via Convertible Bond Issue, Modestly Diluting Shareholders

PuraPharm Corp. Ltd. ( (HK:1498) ) has issued an announcement.

PuraPharm Corporation Limited has completed the issuance of HK$20 million in convertible bonds under its general mandate, following the fulfilment of all conditions in the subscription agreement and the placement of the bonds with a single subscriber. Based on an initial conversion price of HK$0.49 per share, full conversion of these bonds would result in the issue of 40,816,326 new shares, representing about 7.62% of the existing share capital and 7.08% of the enlarged share base, modestly diluting existing holdings while strengthening the company’s funding position.

The company’s major shareholders, including Mr. Chan and various associated entities, will see their combined stake decline from roughly 59.66% to 55.43% upon full conversion, though they would retain majority control. The transaction signals management’s ongoing use of capital market instruments to support operations and potential growth initiatives, with a manageable level of dilution that existing investors will need to factor into their ownership and voting power assessments.

The most recent analyst rating on (HK:1498) stock is a Sell with a HK$0.33 price target. To see the full list of analyst forecasts on PuraPharm Corp. Ltd. stock, see the HK:1498 Stock Forecast page.

More about PuraPharm Corp. Ltd.

PuraPharm Corporation Limited is a Hong Kong-listed company engaged in the healthcare and pharmaceutical sector, with a focus on products rooted in traditional Chinese medicine. The group targets consumers seeking clinically backed, standardized herbal and wellness solutions in Greater China and related markets.

Average Trading Volume: 218,440

Technical Sentiment Signal: Sell

Current Market Cap: HK$168.5M

Learn more about 1498 stock on TipRanks’ Stock Analysis page.